Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study | NIH: National Institute of Allergy and Infectious Diseases

Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study | NIH: National Institute of Allergy and Infectious Diseases

Long-acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study

A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a NIAID-sponsored clinical trial. While both methods were highly effective for HIV prevention in the study population, the final data analysis indicated that cabotegravir had a superior protective effect. Findings from the Phase 2b/3 study, called HPTN 083, were discussed today at an online press conference during the 23^rd International AIDS Conference (AIDS 2020: Virtual).